Actuate Therapeutics, Inc. Common stock Total Assets
Actuate Therapeutics, Inc. Common stock total assets. Based on the latest financial reports, Actuate Therapeutics, Inc. Common stock (ACTU) holds total assets worth $17.71 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Actuate Therapeutics, Inc. Common stock (ACTU) total market value for the company's overall valuation and market capitalisation.
Total Assets of Actuate Therapeutics, Inc. Common stock (2022–2024)
Total assets of Actuate Therapeutics, Inc. Common stock from 2022 to 2024. This chart illustrates how Actuate Therapeutics, Inc. Common stock's total assets have evolved over time, based on quarterly financial data. See Actuate Therapeutics, Inc. Common stock stock quote for real-time trading data and today's change.
Actuate Therapeutics, Inc. Common stock - Asset Composition Analysis
Actuate Therapeutics, Inc. Common stock Total Assets Breakdown (December 2024)
Actuate Therapeutics, Inc. Common stock total assets breakdown as of December 2024. Actuate Therapeutics, Inc. Common stock's total assets of $17.71 Million consist of 98.8% current assets and 1.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Actuate Therapeutics, Inc. Common stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Actuate Therapeutics, Inc. Common stock working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Actuate Therapeutics, Inc. Common stock's current assets represent 98.8% of total assets in 2024, a decrease from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 92.7% of total assets in 2024, down from 99.8% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Actuate Therapeutics, Inc. Common stock Competitors by Total Assets
Key competitors of Actuate Therapeutics, Inc. Common stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Actuate Therapeutics, Inc. Common stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.74 | 1.68 | 0.43 |
| Quick Ratio | 2.74 | 1.68 | 0.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $11.07 Million | $5.77 Million | $-3.93 Million |
Actuate Therapeutics, Inc. Common stock - Advanced Valuation Insights
This section examines the relationship between Actuate Therapeutics, Inc. Common stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.10 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | 211.1% |
| Total Assets | $9.32 Million |
| Market Capitalization | $8.14 Million USD |
Valuation Analysis
Near Book Valuation: The market values Actuate Therapeutics, Inc. Common stock's assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Actuate Therapeutics, Inc. Common stock's assets grew by 211.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Actuate Therapeutics, Inc. Common stock (2022–2024)
The table below shows the annual total assets of Actuate Therapeutics, Inc. Common stock from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $9.32 Million | +211.07% |
| 2023-12-31 | $3.00 Million | -85.38% |
| 2022-12-31 | $20.48 Million | -- |
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of… Read more